ArticleJournal of hepatocellular carcinoma2026
Baseline ALBI Grade as an Independent Prognostic Factor of Survival in High-Risk Real-World HCC Under Atezolizumab-Bevacizumab.
Filiz Araz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.